Bertagnolli: NCI is bracing for flat funding over the next two years

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Thomas J. Lynch Jr. and Howard A. “Skip” Burris III lead two institutions that couldn’t be more different—an NCI-designated Comprehensive Cancer Center on one side of the country and a for-profit research enterprise on the other—but they stay up at nights worrying about the same thing.

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Natalie Phelps, a 43-year-old mother of two, has stage 4 colorectal cancer. She has become a central figure in the controversy over the dysfunction the Trump administration’s RIFs and budget cuts have brought to NIH.

An opportunity for Trump: Position U.S. cancer science to lead the world

Last November, the American public voted on America First causes, which include the greatest scientific discovery and achievement enterprise in the world: The National Institutes of Health. NIH has made America first in biomedical science for the past century.

May 16, 2025

Vol.51 No.19

By Wafik S. El-Deiry

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

How is the enterprise of cancer research doing after the first 100 days of the Trump administration?

May 09, 2025

Vol.51 No.18

By Paul Goldberg and Jacquelyn Cobb

Cancer Policy

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Over $180 million in NCI grants have been terminated between Feb. 28 and April 8, according to a systematic review published in JAMA May 8.

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Researchers at NCI have completed a comprehensive analysis of cancer statistics for different age groups in the United States and found that from 2010 through 2019, the incidence of 14 cancer types increased among people under age 50.

May 09, 2025

Vol.51 No.18

Bertagnolli: NCI is bracing for flat funding over the next two years

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

An opportunity for Trump: Position U.S. cancer science to lead the world

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Renew today!

Subscriber content

Never miss an issue!

Login

Bertagnolli: NCI is bracing for flat funding over the next two years

YOU MAY BE INTERESTED IN

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient livesIn a time of uncertainty, “react to the knowns, not the fear”

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reducedNCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

An opportunity for Trump: Position U.S. cancer science to lead the world

Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit

$180M in NCI grants have been terminated by Trump administration, systematic review finds

Incidence rates of some cancer types have risen in people under age 50, NCI study shows

Never miss an issue!

Login

The Directors: Tom Lynch and Skip Burris on how NIH funding cuts imperil biopharma innovation—and cost patient lives
In a time of uncertainty, “react to the knowns, not the fear”

Kennedy’s claims notwithstanding, NCI clinical trials are delayed, enrollments reduced
NCI’s Steven A. Rosenberg: “Almost all patients are getting delayed by about a month, but then again, we’re turning away more patients.”

Trump administration is removing the mainstays of NCI and the federal government’s cancer program
Peer review, registries, and evidence-based patient information take a big hit